Deutsche Bank AG Has $3.92 Million Stake in Krystal Biotech, Inc. $KRYS

Deutsche Bank AG reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 14.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 21,737 shares of the company’s stock after selling 3,624 shares during the period. Deutsche Bank AG owned about 0.08% of Krystal Biotech worth $3,919,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in KRYS. Fifth Third Bancorp grew its holdings in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after purchasing an additional 105 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech during the fourth quarter worth about $95,000. GAMMA Investing LLC grew its holdings in shares of Krystal Biotech by 179.3% during the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock worth $121,000 after purchasing an additional 432 shares during the last quarter. Elevation Point Wealth Partners LLC bought a new stake in shares of Krystal Biotech during the first quarter worth about $223,000. Finally, Avanza Fonder AB grew its holdings in shares of Krystal Biotech by 66.0% during the first quarter. Avanza Fonder AB now owns 1,260 shares of the company’s stock worth $228,000 after purchasing an additional 501 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on KRYS. Guggenheim reduced their price target on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. HC Wainwright reiterated a “buy” rating and issued a $240.00 target price on shares of Krystal Biotech in a report on Friday, July 25th. Citigroup reiterated a “neutral” rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a report on Tuesday, August 5th. Chardan Capital reiterated a “buy” rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Tuesday, August 5th. Finally, Bank of America reduced their target price on Krystal Biotech from $193.00 to $192.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Krystal Biotech currently has a consensus rating of “Buy” and an average price target of $210.75.

Insider Activity

In other Krystal Biotech news, insider Suma Krishnan sold 13,435 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $150.30, for a total transaction of $2,019,280.50. Following the transaction, the insider directly owned 1,443,276 shares in the company, valued at approximately $216,924,382.80. This represents a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 49,800 shares of company stock worth $7,487,943. 13.70% of the stock is currently owned by corporate insiders.

Krystal Biotech Stock Performance

Krystal Biotech stock opened at $146.30 on Tuesday. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of 29.74 and a beta of 0.70. Krystal Biotech, Inc. has a 52-week low of $122.80 and a 52-week high of $207.84. The stock’s 50 day moving average price is $143.61 and its two-hundred day moving average price is $154.90.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Monday, August 4th. The company reported $1.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.21. The firm had revenue of $96.04 million for the quarter, compared to analysts’ expectations of $95.42 million. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%. On average, equities research analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).